Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Dimopoulos

Showing results (231-240 of 288) with videos related to

Pageof 29
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.
Gynecologic Oncology|November 27, 2007
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapyAristotelis Bamias, Vasiliki Koutsoukou, Evangelos Terpos, et al.
Leukemia|July 24, 2009
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaM A Dimopoulos, C Chen, A Spencer, et al.
Acta Haematologica|April 2, 2005
Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 casesT Economopoulos, S Papageorgiou, M A Dimopoulos, et al.
British Journal of Cancer|November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2N G Gavalas, M Tsiatas, O Tsitsilonis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal functionM A Dimopoulos, E Kastritis, E Michalis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trialV Georgoulias, C Kouroussis, N Androulakis, et al.
Oncology|June 6, 2000
Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experienceD Pectasides, T Economopoulos, G Kouvatseas, et al.
Gynecologic Oncology|April 17, 2007
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistanceA Bamias, M L Tsiatas, E Kafantari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2005
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) studyG Aravantinos, G Fountzilas, P Kosmidis, et al.
Pageof 29

Showing results (231-240 of 288) with videos related to

Sort By:
Pageof 29
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.
Gynecologic Oncology|November 27, 2007
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapyAristotelis Bamias, Vasiliki Koutsoukou, Evangelos Terpos, et al.
Leukemia|July 24, 2009
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaM A Dimopoulos, C Chen, A Spencer, et al.
Acta Haematologica|April 2, 2005
Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 casesT Economopoulos, S Papageorgiou, M A Dimopoulos, et al.
British Journal of Cancer|November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2N G Gavalas, M Tsiatas, O Tsitsilonis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal functionM A Dimopoulos, E Kastritis, E Michalis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trialV Georgoulias, C Kouroussis, N Androulakis, et al.
Oncology|June 6, 2000
Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experienceD Pectasides, T Economopoulos, G Kouvatseas, et al.
Gynecologic Oncology|April 17, 2007
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistanceA Bamias, M L Tsiatas, E Kafantari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2005
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) studyG Aravantinos, G Fountzilas, P Kosmidis, et al.
Pageof 29